New Report Available: Indonesia Pharmaceuticals & Healthcare Report Q4 2014

Indonesia is one of the most promising markets for the pharmaceutical and healthcare companies in South East Asia. The country's large population, positive economic outlook and considerable disease burden bode well for growth in demand for drugs, medical devices and healthcare services. The ongoing implementation of the universal healthcare scheme in Indonesia coupled with the impending launch of the ASEAN Economic Community will provide growth opportunities for pharmaceutical firms. However , we highlight that the universal healthcare scheme is still in its infancy, therefore it will take some time before pharmaceutical firms can reap rewards.

Headline Expenditure Projections

* Pharmaceuticals: IDR63,806bn (USD6.11bn) in 2013 to IDR69,480bn (USD5.89bn) in 2014; +8.9% growth in local currency terms and -3.8% in US dollar terms. Forecast broadly in line with previous quarter.
* Healthcare: IDR285,776bn (USD27.35bn) in 2013 to IDR325,404bn (USD28.87bn) in 2014; +13.9% growth in local currency terms and +5.6% in US dollar terms. Forecast unchanged from previous quarter .

Full Report Details at
- http://www.fastmr.com/prod/900711_indonesia_pharmaceuticals_healthcare_report_q4.aspx?afid=301

Risk/Reward Rating

In our latest Q414 proprietary Pharmaceutical Risk/Reward Rating (RRR) ratings, Indonesia ranks 13th out of the 19 Asia Pacific markets. Though its Rewards are considered to be above than the regional average, Indonesia's Risks profile is considerably more unfavourable, which will continue to detract foreign players from investing in the country's pharmaceutical market.

Key Trends And Developments

* In August 2014, local media, the Jakarta Post stated that Indonesia's Health Ministry is in discussions with the Finance Ministry regarding adjustment of some healthcare services fees in the Indonesian Case Based Groups scheme of Social Security Agency for Health (BPJS Kesehatan). The agency has already discussed the rate adjustment with public and private hospitals, including medical professionals, stated Pardede. However, concerns remain regarding explanation of...

The Indonesia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Indonesia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Indonesian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Indonesia to test other views - a key input for successful budgeting and strategic business planning in the Indonesian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Greece Pharmaceuticals & Healthcare Report Q4 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2014